Moberg Pharma AB (OSTO:MOB) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:MOB Moberg Pharma AB OSTO:MOB
59 GF Score
Price kr9.25
GF Value kr12.45
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Moberg Pharma AB FFO per Share?

FFO per Share only applies to REITs.

OSTO:MOB
59GF Score
Moberg Pharma AB OSTO:MOB
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Moberg Pharma AB (OSTO:MOB) Overvalued in 2026?

Based on GuruFocus' analysis, Moberg Pharma AB stock appears to be undervalued. The current stock price of kr9.25 is trading 25.7% below its estimated GF Value™ of kr12.45. GuruFocus considers Moberg Pharma AB to be Modestly Undervalued.

Key valuation signals for OSTO:MOB:

  • FFO per Share:
  • GF Value™: kr12.45 vs. price of kr9.25 (25.7% below fair value)
  • GF Score™: 59/100 with 1 warning sign

No single metric tells the full story. See the OSTO:MOB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Moberg Pharma AB Business Description

Other Exchanges MBGPF:USA
Address Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
59GF Score

Get the complete analysis for OSTO:MOB

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr9.25
Price
kr12.45
GF Value